They inconsistently reported variables such as tumor size, number of lesions, serum CEA levels, synchronous versus metachronous presentation, nodal status of the primary tumor, and receipt of neoadjuvant chemotherapy. The gene discussed is CEACAM5; the disease is neoplasm.